Venous thromboembolism in lymphoma patients

Darko Antic, Jelena Jelicic, Vojin Vukovic, Srdjan Nikolovski, Biljana Mihaljevic

Overview

Lymphoma, as a malignant disorder, increases the risk of thrombotic complications and those complications significantly affect morbidity of patients. Additionally, thromboembolic events are one of the leading causes of death among patients with malignancy in general.

Summary

This review emphasizes several practice points in managing lymphoma patients with thromboembolic complications: • Thromboprophylaxis in lymphoma patients are underused. • Use of anticoagulation drugs in patients with lymphoma requires monitoring of blood count, kidney function, as well as drug–drug interactions. • The Thrombosis Lymphoma (ThroLy) score has been shown to be more precise for lymphoma patients than any other available score targeting thrombosis risk in cancer patients developed so far. • Use of direct oral anticoagulants in lymphoma patients is still under debate and requires a multidisciplinary approach.

Altmetric Statistics

Author Comments

Dr. Srdjan Nikolovski, MD
Dr. Srdjan Nikolovski, MD
Clinical Center Serbia, University Children's Hospital, School of Medicine University of Belgrade
Research Associate
Clinical Research
Belgrade, Serbia | Yugoslavia
The purpose of this article is to present a comprehensive view of management of lymphoma patients with thromboembolic complications or an increased risk for thromboembolism. Previously developed ThroLy score served as a perfect basis for discussing all aspects of this particular topic. Also, this article showed the importance and necessity of multidisciplinary approach, patient's full compliance, as well as careful monitoring of potential chemotherapy-drug toxicity.Dr. Srdjan Nikolovski, MD

Resources

Article Web Page
https://www.sciencedirect.com/science/article/abs/pii/S0268960X17300048?via%3Dihub

Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment.

Authors:
Dr. Srdjan Nikolovski, MD
Dr. Srdjan Nikolovski, MD
Clinical Center Serbia, University Children's Hospital, School of Medicine University of Belgrade
Research Associate
Clinical Research
Belgrade, Serbia | Yugoslavia

Blood Rev 2018 03 31;32(2):144-158. Epub 2017 Oct 31.

Clinic for Hematology, Clinical Centre Serbia, Belgrade, Serbia; Medical Faculty, University of Belgrade, Belgrade, Serbia.

Venous thromboembolic events (VTE) are an underestimated health problem in patients with lymphoma. Many factors contribute to the pathogenesis of thromboembolism and the interplay between various mechanisms that provoke VTE is still poorly understood. The identification of parameters that are associated with an increased risk of VTE in lymphoma patients led to the creation of several risk-assessment models. The models that evaluate potential VTE risk in lymphoma patients in particular are quite limited, and have to be validated in larger study populations. Furthermore, the VTE prophylaxis in lymphoma patients is largely underused, despite the incidence of VTE. The lack of adequate guidelines for the prophylaxis and treatment of VTE in lymphoma patients, together with a cautious approach due to an increased risk of bleeding, demands great efforts to ensure the implementation of current knowledge in order to reduce the incidence and complications of VTE in lymphoma patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2017.10.002DOI Listing
March 2018
8 Reads
1 Citation
5.570 Impact Factor

Publication Analysis

Top Keywords

lymphoma patients
24
vte lymphoma
12
vte
8
thromboembolic events
8
increased risk
8
venous thromboembolic
8
lymphoma
7
patients
7
associated increased
4
incidence vte
4
parameters associated
4
vte lack
4
patients led
4
despite incidence
4
risk vte
4
adequate guidelines
4
provoke vte
4
mechanisms provoke
4
prophylaxis treatment
4
guidelines prophylaxis
4

Similar Publications